Dr. Reddy's Share Price in Focus as Health Canada Approves First Generic Semaglutide Injection; Canada Becomes First G7 Nation to Authorise

Health Canada has approved the first generic version of the semaglutide injection produced by Dr. Reddy's Laboratories, making Canada the first G7 nation to make this move.  

The authorisation could result in a notable reduction in medication costs for diabetes management. 

Health Canada's Approval Process 

On April 28, 2026, Health Canada authorised the generic semaglutide injection, which is produced by Dr. Reddy's Laboratories.  

This decision followed a comprehensive review verifying that the generic meets the safety, efficacy, and quality standards expected of generic pharmaceuticals. 

The drug offers equivalent therapeutic benefits as the branded version known as Ozempic. 

Implications for Patients and Healthcare Costs 

This development is expected to benefit patients with type 2 diabetes by providing an affordable alternative for managing blood sugar levels.  

Generic medicines in Canada often cost 45 to 90% less than their brand-name counterparts, potentially alleviating financial pressures on patients and the healthcare system. 

Read More: Dr Reddy’s Shares Rise 7%; What Is Driving the Rally? 

Ongoing Monitoring and Future Reviews 

Health Canada will maintain oversight of the generic semaglutide to ensure it remains safe and effective for users.  

As of now, they are examining 8 additional submissions for other generic versions of semaglutide from different companies, with decisions expected in subsequent months. Such regulatory activities affirm the commitment to maintaining high standards in drug approvals. 

Dr. Reddy's Laboratories Share Price Performance 

As of April 29, 2026, at 9:16 AM, Dr. Reddy's Laboratories share price on NSE was trading at ₹1,367.10 up by 0.92% from the previous closing price.  

Conclusion 

Canada's approval of the first generic semaglutide injection produced by Dr. Reddy's Laboratories marks a significant step in the availability of cost-effective diabetic treatments in G7 countries. This decision aligns with efforts to reduce medication costs while ensuring patients have access to safe and effective treatments. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.